A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant

Jew, Win Kuan and Chiong, Soon Law and Xiang, Qi Wong and Ching, Tiong Ko and Zool, Hilmi Awang and Lee, Ping Chew and Kian-Meng, Chang (2016) A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant. Applied Radiation and Isotopes, 116. pp. 13-21. ISSN 0969-8043

[img]
Preview
PDF
A pioneerexperienceinMalaysiaonIn-houseRadio-labelling(abstract).pdf

Download (111kB) | Preview

Abstract

Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – 90Y-ibritumomab tiuxetan is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling 131I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling 131I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose 131I-rituximab (6000 MBq/163 mCi) combined with BEAM conditioning for autologous HSCT.

Item Type: Article
Uncontrolled Keywords: Radioimmunotherapy, 131I-rituximab, Iodine-131, Rituximab, Non-Hodgkin's lymphoma, unimas, university, universiti, Borneo, Malaysia, Sarawak, Kuching, Samarahan, ipta, education, research, Universiti Malaysia Sarawak
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Academic Faculties, Institutes and Centres > Faculty of Medicine and Health Sciences
Depositing User: Karen Kornalius
Date Deposited: 03 Aug 2016 22:30
Last Modified: 20 Sep 2016 16:46
URI: http://ir.unimas.my/id/eprint/12763

Actions (For repository members only: login required)

View Item View Item